Cargando…

Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer

SIMPLE SUMMARY: At a genomic level metastatic castrate resistant prostate cancer state is highly heterogeneous and no clear genome-based prognostic or predictive biomarkers exist in practice. We evaluated multiple copy number somatic alterations in two castrate resistant patient cohorts to determine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jinyong, Du, Meijun, Soupir, Alex, Wang, Liewei, Tan, Winston, Kalari, Krishna R., Kilari, Deepak, Park, Jong, Huang, Chiang-Ching, Kohli, Manish, Wang, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562906/ https://www.ncbi.nlm.nih.gov/pubmed/36230636 http://dx.doi.org/10.3390/cancers14194714

Ejemplares similares

Plasma cell-free DNA–based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer
por: Du, Meijun, et al.
Publicado: (2020)

Prognostic association of plasma cell free DNA based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration resistant prostate cancer patients
por: Kohli, Manish, et al.
Publicado: (2018)

Multiplex Digital PCR to Detect Amplifications of Specific Androgen Receptor Loci in Cell-Free DNA for Prognosis of Metastatic Castration-Resistant Prostate Cancer
por: Du, Meijun, et al.
Publicado: (2020)

Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer
por: Du, Meijun, et al.
Publicado: (2017)

Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer
por: Xia, Yun, et al.
Publicado: (2016)

Copy number variation and cytidine analogue cytotoxicity: A genome-wide association approach
por: Kalari, Krishna R, et al.
Publicado: (2010)

Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
por: Sicotte, Hugues, et al.
Publicado: (2022)

Genetic Association Studies of Copy-Number Variation: Should Assignment of Copy Number States Precede Testing?
por: Breheny, Patrick, et al.
Publicado: (2012)

A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens
por: Jimenez, Rafael E., et al.
Publicado: (2019)

Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer
por: Hart, Steven N, et al.
Publicado: (2016)

Cell‐free DNA copy number variations in plasma from colorectal cancer patients
por: Li, Jian, et al.
Publicado: (2017)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer
por: Tan, Winston, et al.
Publicado: (2022)

Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer
por: Giridhar, Karthik V., et al.
Publicado: (2018)

TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration‐Resistant Prostate Cancer
por: Qin, Sisi, et al.
Publicado: (2017)

5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapy
por: Li, Qianxia, et al.
Publicado: (2023)

Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer
por: Dong, Xiaoxi, et al.
Publicado: (2021)

Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer
por: Qin, Sisi, et al.
Publicado: (2022)

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Binder, Moritz, et al.
Publicado: (2016)

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation
por: Kmak, Jamie A., et al.
Publicado: (2020)

Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer
por: Xia, Shu, et al.
Publicado: (2015)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance
por: Emad, Amin, et al.
Publicado: (2017)

An Improved Detection of Circulating Tumor DNA in Extracellular Vesicles-Depleted Plasma
por: Sun, Li, et al.
Publicado: (2021)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

Copy number profiles of paired primary and metastatic colorectal cancers
por: Kawamata, Futoshi, et al.
Publicado: (2017)

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
por: Kohli, Manish, et al.
Publicado: (2020)

Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer
por: Liu, Wennuan, et al.
Publicado: (2009)

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
por: Salvi, S, et al.
Publicado: (2015)

Polygenic risk scores in schizophrenia with clinically significant copy number variants
por: Taniguchi, Satoru, et al.
Publicado: (2019)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014)

Copy Number Variations in Female Infertility in China
por: Huang, W, et al.
Publicado: (2019)

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
por: Hwang, Clara, et al.
Publicado: (2023)

Copy number polymorphisms and anticancer pharmacogenomics
por: Gamazon, Eric R, et al.
Publicado: (2011)

Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer
por: Lyng, Heidi, et al.
Publicado: (2006)

DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors
por: Bambury, Richard M, et al.
Publicado: (2015)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Identification of genetic variants or genes that are associated with Homoharringtonine (HHT) response through a genome-wide association study in human lymphoblastoid cell lines (LCLs)
por: Tong, Yin, et al.
Publicado: (2015)

Cell-level somatic mutation detection from single-cell RNA sequencing
por: Vu, Trung Nghia, et al.
Publicado: (2019)

CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer
por: Cairns, Junmei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vfiqsml08g7mq05q61u41s1f6a